Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18711692 | 0.62 | SPR (0.48) | PARP1PARP15PARP3ALDH1A1L3MBTL1 | |
| SCHEMBL6173406 | 0.61 | — | — | |
| SCHEMBL5253471 | 0.61 | PARP1 (0.38) | PARP1PARP15PARP3CYP1A2HIF1A | |
| SCHEMBL18711836 | 0.60 | PARP1 (0.62) | PARP1PARP15PARP3ALDH1A1L3MBTL1 | |
| SCHEMBL3122203 | 0.57 | PARP1 (0.59) | PARP1PARP15PARP3ALDH1A1CYP1A2 | |
| SCHEMBL10150407 | 0.57 | PARP1 (0.59) | PARP1PARP15PARP3ALDH1A1L3MBTL1 | |
| SCHEMBL18711684 | 0.56 | PARP1 (0.49) | PARP1PARP15PARP3ALDH1A1L3MBTL1 | |
| SCHEMBL31077649 | 0.56 | PARP1 (0.37) | PARP1PARP15PARP3ALDH1A1L3MBTL1 | |
| SCHEMBL12527448 | 0.55 | PARP1 (0.47) | PARP1PARP15PARP3ALDH1A1L3MBTL1 | |
| SCHEMBL31233486 | 0.55 | PARP1 (0.41) | PARP1PARP15PARP3ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615848-A1 | COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND USES THEREOF | Ribometrix, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| US-20240246918-A1 | COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND THE USES THEREOF | RIBOMETRIX, INC. | 2024-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246918-A1 | COMPOUNDS AND COMPOSITIONS AS EIF4E INHIBITORS AND THE USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | PARP1 1812/4885PARP15 1737/4885PARP3 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.